This data de-risks the ongoing pivotal EMBRAVE3 trial and positions elsunersen as a best-in-class candidate for SCN2A-DEE. Traders should monitor upcoming regulatory interactions and potential fast-track expansion; consider positioning ahead of EMBRAVE3 readout. Competitive moat strengthened by PRIME and orphan designations in both US and EU.
Price Chart
Executive Summary
Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with SCN2A developmental and epileptic encephalopathy (DEE), showing a 77% placebo-adjusted seizure reduction (p=0.015) and meaningful functional improvements across sleep, motor function, and attention. The drug was well-tolerated with no drug-related serious adverse events, supporting its potential as a first disease-modifying therapy for this rare genetic epilepsy.
Key Facts
- Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in SCN2A-DEE patients
- 71% of treated patients had >50% seizure reduction; 57% had at least 28 days seizure-free
- 100% of elsunersen patients showed functional improvements vs. none in placebo
- No treatment-emergent or serious adverse events related to the drug
- All nine patients continued into open-label extension with sustained benefit up to one year
Financial Impact
High-value catalyst for a rare disease with no approved therapies; potential peak sales in the hundreds of millions given orphan drug designations and precision CNS focus
Risk Factors
- Small sample size (n=9) limits statistical power despite significance
- Pivotal EMBRAVE3 trial results may not replicate Part A efficacy
- Regulatory path may require additional data beyond current trial design
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268372 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 29, 2026 13w ago | 8-K | $334.79 $282.12 | ▲ +15.73% | ▲ +18.55% | $292.66 (+12.58%) |
Jun 11, 2026 16w ago | Institutional Cluster | $247.98 $351.81 | ▲ +41.87% | ▲ +37.47% | $292.66 (+18.02%) |
Jun 2, 2026 17w ago | Press Release | $278.93 $367.85 | ▲ +31.88% | ▲ +29.38% | $292.66 (+4.92%) |
May 7, 2026 21w ago | Press Release | $333.28 $305.51 | ▼ −8.33% | ▼ −12.17% | $292.66 (−12.19%) |
May 4, 2026 21w ago | Press Release | $333.30 $307.75 | ▼ −7.67% | ▼ −10.41% | $292.66 (−12.19%) |
Apr 14, 2026 24w ago | Press Release | $343.60 $333.12 | ▼ −3.05% | ▼ −11.57% | $292.66 (−14.83%) |
Apr 6, 2026 25w ago | Press Release | $310.11 $319.60 | ▲ +3.06% | ▼ −10.41% | $292.66 (−5.63%) |
Mar 30, 2026 26w ago | Press Release | $322.19 $327.79 | ▲ +1.74% | ▼ −10.64% | $292.66 (−9.17%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access